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Neuroinflammation, meaning the establishment of a diffuse inflammatory condition in 
the CNS, is one of the main hallmarks of amyotrophic lateral sclerosis (ALS). Recently, 
a crucial role of regulatory T cells (Tregs) in this disease has been outlined. Tregs are a 
T cell subpopulation with immunomodulatory properties. In this review, we discuss the 
physiology of Tregs and their role in ALS disease onset and progression. Evidence has 
demonstrated that in ALS patients Tregs are dramatically and progressively reduced in 
number and are less effective in promoting immune suppression. In addition, Tregs 
levels correlate with the rate of disease progression and patient survival. For this reason, 
Tregs are now considered a promising therapeutic target for neuroprotection in ALS. In 
this review, the clinical impact of these cells will be discussed and an overview of the 
current clinical trials targeting Tregs is also provided. 
Keywords: amyotrophic lateral sclerosis, neuroinflammation, neuroimmunology, 
regulatory T cells, clinical trials. 
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Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterised 
by the progressive loss of both upper and lower motor neurons which causes death 
usually within 3-5 years of diagnosis (1). Currently, there is no effective disease 
modifying treatment available (2). Riluzole, is the only available drug which has been 
approved by both the U.S. Food and Drug Administration (FDA) and the European 
Medicine Agency (EMA). However, riluzole only extends patients survival by 3 months 
on average (3, 4). Edaravone, a free-radical scavenger, was approved by the FDA for 
the treatment of ALS, although, longer-term effects of this drug are still to be evaluated 
(https://www.fda.gov/news-events/press-announcements/fda-approves-drug-treat-als, 5, 
6).
ALS is considered a multifactorial disease as a series of mechanisms and pathways are 
implicated in the disease (7, 8). Among them, neuroinflammation is perceived as a 
dysregulation of the glial cells which surround neurons in the CNS and which can create 
an inflammatory milieu. Its main features are: activation of microglia and astrocytes, 
production of excessive quantities of pro-inflammatory cytokines and infiltration by T 
lymphocytes (9). Recently, a key role for regulatory T cells (Tregs) in the 
pathophysiology of ALS has been demonstrated.
Physiology of regulatory T cells
Tregs are fundamental modulators of the immune response: they maintain self-tolerance 
and homeostasis, preventing the onset of autoimmune diseases. These cells are 
generally classified into two subgroups: thymus-derived and peripheral inducible (10). 
The first subtype is produced in the thymus during the negative selection process; they 
then migrate into peripheral tissues to perform their functions. They are also known as 
Page 3 of 23
URL: http://mc.manuscriptcentral.com/als  Email: gerd.halvorsen@informa.com
































































naturally occurring or CD4+CD25+ Tregs because of the surface molecules they express. 
The presence of CD25+, also referred to as interleukin-2 receptor alpha (IL2RA), 
indicates the importance of IL-2 for Treg functions (10). Another key feature of these 
cells is the expression of Forkhead box protein 3 (FOXP3) (11). The second subtype of 
Tregs are peripheral in origin. These cells are derived by antigen-exposed CD4+ T cells 
in peripheral tissues following the exposure to specific molecules. Induced CD4+ Tregs 
can be further classified into FOXP3+ or FOXP3- cells (12). 
Clearly, FOXP3 has a crucial role for Tregs. It is a transcriptional regulator which is 
fundamental for their development and function. It can act both as a transcriptional 
activator or repressor because it interacts with several transcription factors and proteins 
involved in epigenetic regulation (13). In particular, it prevents the transcription of pro-
inflammatory cytokines such as IL-2 and IFN- and it concomitantly activates immune 
suppressors including cytotoxic T lymphocyte antigen 4 (CTLA4) (13). Furthermore, 
other key markers for Tregs are glucocorticoid-induced tumour necrosis factor receptor 
(GITR) and inducible T cell co-stimulator (ICOS). GITR, also referred to as 
TNFRSF18, plays a role in Treg suppressive activities, in fact, antibodies against GITR 
can abrogate Treg immune modulatory functions, and it is also crucial for thymus Tregs 
differentiation process (14, 15, 16). ICOS is a costimulatory molecule which is known 
to exert various roles within the immune system, participating both to inflammatory and 
suppressive processes (17). However, ICOS appears to play a role in Treg functions. In 
fact, the blockage of ICOS interaction with its ligand (ICOSL) causes a decrease in the 
expression of CTLA4 and ICOS deficiency induces reduction in FOXP3 expression (18, 
19). 
Another key mediator of Treg activity is IL-2. This cytokine is known to be essential for 
the development and survival of these cells (20). Although IL-2 is known to exert 
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pleiotropic functions on the immune system, evidence from IL-2 or IL-2 receptor (IL-
2R) knockout mouse models, demonstrates that these mice do not develop immune 
deficiency syndromes, but they do show features of autoimmune diseases (21). IL-2 
administration promotes the activation of different pathways in effectors T cells (Teffs) 
and Tregs. In fact, the binding of this cytokine with its receptor in Teffs results in the 
activation of STAT5 and S6 kinases, which triggers PI3K-Akt and mTOR pathways. In 
contrast, in Tregs, IL-2 binding mediates direct activation of STAT5 and then FOXP3 
becomes functional (22). Interestingly, it seems that after administration of low-dose IL-
2 (ld-IL-2), there is a selective increase in phosphorylation, and thus activation, of 
STAT5 in Tregs, which corr sponds to a decrease in the same modification in Teffs 
(23). Consistent with this, multiple studies demonstrate that low-dose IL-2-based 
treatment promotes the selective expansion of the Treg population in both mice and 
humans (24), (25), (26).
Tregs exert several immunosuppressive functions: they suppress Teffs, B cells, natural 
killer cells (NKs) and antigen-presenting cells by inhibiting their activation, 
proliferation and function (27).  Moreover, they can alter the activation state of 
microglia/macrophages by promoting the M2 (or anti-inflammatory) phenotype (28).
Several mechanisms have been proposed to mediate these functions (Figure 1):
 Inhibitory cytokine release: Tregs can secrete anti-inflammatory cytokines 
including IL-10, IL-35 and TGF- which inhibit the function of Teffs (29).
 Cytolysis induction: Tregs are able to produce and release granzyme B and 
perforin which induce cytolysis and apoptosis in Teffs, B cells and NKs (30), 
(31), (32).
 Metabolic disruption: This proposed mechanism is based on the consumption of 
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local IL-2 by Tregs. This would cause the deprivation of this cytokine which is 
necessary for Teffs, leading to Teffs IL-2-deprivation-mediated apoptosis (33), 
(34). 
 CTLA4-mediated mechanism: Tregs can physically interact with dendritic cells 
(DC) due to the binding of CTLA4 on the Treg surface and the co-stimulatory 
molecules CD80/CD86 expressed by DC. This leads to the production of 
indoleamine 2,3-dioxygenase (IDO) in DC, a potent immune regulator which 
suppress T cells and NKs (35), (36). 
 cAMP-mediated mechanism: Tregs express high levels of cAMP and this 
molecule can be transferred to Teffs through gap junctions. This provokes the 
activation of inducible cAMP early repressor (ICER) which inhibits nuclear 
factor of activated T cells (NFAT), a transcription factor which is necessary for 
IL-2 production. Thus, this can lead to IL-2 deprivation-mediated apoptosis (37), 
(38). 
Regulatory T cells in ALS
Evidence demonstrates a key role for Tregs in ALS disease onset and progression. In 
2009, a dramatic decrease in the number of CD4+CD25+ Tregs in the peripheral blood 
of sporadic ALS patients was first reported (39). Since then, several laboratories have 
been studying these cell types and their possible role in ALS. 
Changes in the Treg population over the disease course were demonstrated in mutant 
SOD1 (mSOD1) mouse models of ALS. In particular, in an early phase of the disease 
the number of CD4+CD25+ and CD25+FOXP3+ Tregs is increased while, as the disease 
progresses, they gradually decrease. More precisely, in 18-week old mice which reflect 
a later disease phase, a shift from the neuroprotective Treg/Th2 and M2 (“alternatively 
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activated” or anti-inflammatory) microglia population to a neurotoxic Th1/M1 
(“classically activated” or inflammatory) phenotype is detected, and this enhances 
disease progression (40, 41). In fact, in the early phase of the disease Tregs appear to be 
functionally active and able to inhibit the activation of microglia through the secretion 
of IL-4. This cytokine is not entirely secreted by Tregs but also by Th2 and so, this 
latter cell type is also crucial for neuroprotection. Moreover, a mixture of IL-4, IL-10 
and TGF- is required to suppress Teffs. (41). On the contrary, as the disease 
progresses, an increased expression of NOX2, IL-1 and IL-12, which are markers of 
M1 microglia activation, and of IFN-, secreted by Th1, was reported. Moreover, an 
elevation in the levels of IL-6, which can completely inhibit Tregs, was detected (40). 
Interestingly, the passive transfer of healthy Tregs to mSOD1 mice seems to prolong the 
early phase and extend survival (40).
Given this background but also considering the limitation that findings in disease 
models may not translate to humans,  it was questioned what was the role of Tregs in 
ALS patients. Tregs were found to be significantly decreased in their peripheral blood 
(42), perhaps as an attempt of the CNS to recruit Tregs to suppress neuroinflammation, 
which correlates with an increase of Tregs in the CNS in the early disease phase. 
However, as disease progresses, this compensatory attempt fails and Tregs are inhibited 
and decrease in number (42) (Figure 2). Moreover, the quantity of Tregs in the 
peripheral blood negatively correlates with the ALSFRS-R score, a questionnaire used 
to rate the stage and progression of the disease (43). Thus, a lower Treg count is 
associated with a poor ALSFRS-R score and a more aggressive disease course (40, 42). 
Moreover, the percentage of Treg in patient blood also negatively correlates with ALS 
progression expressed in terms of AALS (Appel ALS score) an ALS clinal rating scale 
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(44, 45, 46). This score is independent from ALSFS-R and thus this finding reinforces 
the hypothesis of a Treg disfunction occurring over time in ALS patients.  
Interestingly, Tregs were found not only to be reduced in number but they also appear 
dysfunctional and less effective in promoting Teffs suppression and this dysfunction is 
more evident in rapidly progressing patients (44). In fact, the expression of key genes 
for the normal function of Tregs such as FOXP3, CD25, GATA3 and some anti-
inflammatory cytokines including: TGF-, IL-10 and IL-4, were found to be all 
downregulated in the peripheral blood of rapidly progressive ALS patients. Thus, their 
expression levels were found to be inversely correlated with the disease progression 
rate. Moreover, FOXP3 could be considered a prognostic factor since its levels can 
efficiently predict the speed of disease. (46). Furthermore, evidence of epigenetic 
alteration in TSDR, a CpG-rich regulatory region within the first intron of FOXP3 gene, 
was documented in ALS. This element is physiologically demethylated only in Tregs 
which stably express FOXP3 but it is fully methylated in CD4+ T cells. TSDR is 
partially methylated in ALS patients and this modification occurred more significantly 
in rapidly progressive cases (44). 
Recently, evidence demonstrated that Tregs isolated from ALS are not permanently 
impaired but their function can be restored by culturing them in vitro in the presence of 
IL-2 and rapamycin (47). This latter compound is known to suppress the activity of Th1 
and Th17 because it suppresses the mechanistic target of rapamycin (mTOR) signalling 
pathway which is crucial for these cells. In contrast, rapamycin promotes Tregs 
differentiation and proliferation because they are independent from mTOR (48). After 
treatment with IL-2 and rapamycin, Tregs from ALS subjects and healthy controls have 
comparable suppressive functions. Evidence was provided of the generation of a large-
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scale GMP-compliant method for Treg isolation and expansion in the presence of IL-2 
and rapamycin (47). 
More recently, specific Treg subtypes have been correlated with ALS progression rate 
(ALSFRS-R). Tregs can be classified into CD45RO+, functionally active Tregs, and 
CD45RA+ which are resting Tregs. In rapidly progressive patients, reduction in the 
number of CD45RO+ Tregs was reported, and the amount of this cell type can be 
correlated with disease progression (49). 
Furthermore, intraperitoneal injection of rapamycin and IL-2c (IL-2 combined with its 
monoclonal antibody which increases the magnitude and duration of IL-2 activity) in 
mSOD1 mice promoted CD45RO+ Treg expansion and prolonged their survival. In 
addition, a reduction in astrogliosis and microgliosis by 40 and 50% respectively was 
demonstrated together with an increase in FOXP3 and M2 microglia in the spinal cord 
and the sciatic nerve, and increased levels of GATA3 in sciatic nerve of these treated 
mice. Thus, these latter findings establish that Tregs can not only promote 
neuroprotection in the CNS, but they can also exert an equivalent function in the 
periphery (49). 
This body of evidence demonstrate a key role of Tregs and a dual trend during the 
disease course: these cells seem to be increased in an early disease phase, probably as 
an anti-inflammatory attempt made by the CNS, but as disease progresses, Tregs 
progressively and dramatically decrease leading to a worsening in neuroinflammation. 
Moreover, Treg levels can be considered as a prognostic factor of the disease 
progression and survival and enhancing Tregs can probably constitute a promising 
therapeutic strategy. However, the possible effect of this Tregs expansion is still to be 
investigated and, for this reasons, several clinical trials are currently trying to elucidate 
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their efficacy. In addition, research is being conducted alongside the clinical trials to 
elucidate the molecular and immunological effects of this drug on ALS patients. 
Targeting regulatory T cells
Since the role of the immune system in ALS has been documented, different drugs, 
aiming to suppress neuroinflammation, have been screened for the treatment of this 
disease. For example, prednisone, celecoxib, minocycline and thalidomide have been 
evaluated in clinical trials for ALS. Unfortunately all of them failed to show disease 
progression modulation and some of these agents caused serious adverse reactions (50), 
(51), (52), (53). These compounds negatively regulate the overall function of the 
immune system, and thus, it is now believed that indiscriminate immunosuppression is 
not an appropriate therapeutic strategy for ALS. In contrast, drugs which exert 
immunomodulatory effects, aiming to restore the normal neuroimmune homeostasis, are 
considered promising. In this respect, Tregs constitute a new therapeutic target in ALS 
and different clinical trials, which aim to expand the immune modulatory Tregs, are 
reported in this section (Table 1).
Rapamycin
This drug has already been approved by both the FDA and EMA for the prevention of 
organ rejection after transplant. Rapamycin mediates mTOR inhibition which in turns 
promotes Treg differentiation and stimulation of autophagy. Rapamycin facilitates the 
formation of autophagosomes and thus it promotes the clearance of pathological protein 
aggregates which are a prominent feature in ALS (54). As previously mentioned, the 
mTOR pathway is essential for the differentiation of naïve CD4+ T cells into Th1 and 
Th17 subtypes but it is not necessary for Treg development and, for this reason, it is 
believed to induce the expansion of protective Tregs (48). However, conflicting 
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preclinical results have been reported. In fact, while different studies showed rapamycin 
to be neuroprotective by promoting the elimination of protein aggregates in several 
cellular and animal models; in an another one this drug appeared to be harmful for ALS 
mSOD1 mice causing increase in motor disfunctions, acceleration in MN degeneration 
and decrease survival (55, 56, 57, 58, 59). Nonetheless, a phase II clinical trial (RAP-
ALS) is evaluating the effect of rapamycin as add-on therapy to riluzole on 63 ALS 
patients (54, https://clinicaltrials.gov/ct2/show/NCT03359538). Alongside clinical 
assessments, scientific and investigatory outcomes are also scheduled including: 
immune phenotyping, inflammatory cytokines measurements and blood/CSF 
biomarkers evaluation.
Autologous Treg transplant 
Recently, a phase I trial consisting in the autologous transplantation of Tregs has been 
completed. Tregs from were isolated, expanded in vitro and then reinfused 
intravenously for a total of 8 injections. Concomitantly, subcutaneous administration of 
IL-2 (2x105 international units (IU)/m2, 3 times weekly) was performed. Treatment was 
well tolerated although some infections were reported. At the end of the trial, increased 
suppressive properties of Tregs were observed, along with a slowing of disease 
progression (60), https://clinicaltrials.gov/ct2/show/NCT03241784). These promising 
results have boosted the interest in this type of treatment and a 
placebo-controlled phase IIa trial to investigate the effect of autologous Treg infusions 
in combination with low-dose-IL-2 in a larger number of patients is now underway (12, 
https://clinicaltrials.gov/ct2/show/NCT04055623).
RNS60 
RNS60 is an experimental nanostructured drug which consists in different oxygen 
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nanobubbles. Preclinical studies indicate a significant effect of this compound in 
extending survival of mSOD1 mice, as well as protecting their spinal cord motor 
neurons and NMJs from degeneration. These results appear to be due to RNS60 action 
on several ALS pathological mechanisms: i) RNS60 activates the p-Akt pro-survival 
pathway in MN, astrocytes and Schwann cells; ii) it reduces mitochondrial alteration 
and oxidative stress; iii) it promotes M2/Th2 activation over M1/Th1; iv) it induces the 
overproduction of IL-4 and activates Tregs (61). In 2018, a pilot RNS60 phase I clinical 
trial was completed. Sixteen participants were involved who received RNS60 by 
infusions (375ml) once weekly and nebulized RNS60 (4ml/day) for the remaining 6 
days of the week for a total of 18 weeks. Results showed that this drug is safe and well 
tolerated with no adverse events reported throughout the trial. Unfortunately, no 
significant change in IL-17 and FOXP3 expression or differences in neuroimaging 
markers were reported during the treatm nt period. This was probably due to the small 
patient size and the lack of a placebo group (62), 
https://clinicaltrials.gov/ct2/show/NCT02525471). Thus, to further investigate the 
therapeutic potential of RNS60, two different placebo-controlled phase II clinical trials 
are now active evaluating the effect of either intravenous and/or nebulized inhaled 
RNS60 in 142 (https://clinicaltrials.gov/ct2/show/NCT03456882) and 140 
(https://clinicaltrials.gov/ct2/show/NCT02988297) ALS patients respectively.
Vitamin D
Vitamin D (VitD) is believed to have immune-modulatory properties. In particular, this 
vitamin appears to exert functions on Tregs: it promotes Treg differentiation over 
cytotoxic T cells, induces FOXP3 expression and IL-10 secretion (63). Recently, a role 
of VitD in ALS has been proposed. However, contradictory results have emerged. 
While some studies reported that VitD deficiency correlates with a decreased survival, 
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another reported the association between high levels of VitD and worse ALS prognosis 
(64), (65), (66).  Despite these discrepancies, a clinical trial called “T cell phenotype in 
ALS, influence of vitamin D” or VITALS is currently in the recruiting phase. Seventy 
ALS patients and 27 healthy controls will be screened for VitD levels in their blood and 
patients with VitD deficiency will be supplemented with this molecule. 
(https://clinicaltrials.gov/ct2/show/study/NCT02756104). Immune phenotyping will be 
conducted throughout the trial to monitor changes within the T cell population. 
Low-dose IL-2
Although IL-2 is known to exert pleiotropic functions on the immune system, it is a 
crucial mediator of Treg differentiation and survival (20). In particular, ld-IL-2 seems to 
specifically promote Treg expansion without having any significant effects on Teffs 
(23). This can be explained by the different IL-2 receptors these two cell types show on 
their surface membranes. In fact, while Tregs constitutively express high-affinity IL-2R 
(made of three subunits: IL-2RA, IL-2RB and IL-2RG), Teffs express it only after T 
cell receptor (TCR) activation. Without this stimulus, Teffs constitutively express only 
the intermediate-affinity receptor (IL-2RB and IL-2RG). This means that Teffs require 
much more IL-2 to become active compared to Tregs (23, 67). In particular, a study 
shows that the amount of IL-2 required for the activation of Teffs is about 5000 higher 
than the dose required for Tregs (67). For this reason, IL-2 at low doses is able to exert 
a specific expansion effect only on Tregs and it is now under investigation for ALS 
treatment. 
A pilot phase II trial, IMODALS, using two different concentrations of ld-IL2 (1MIU 
and 2MIU) in combination with riluzole was undertaken. Although the recruiting phase 
of this trial is completed, the results of the study are still to be published 
(https://clinicaltrials.gov/ct2/show/NCT02059759).
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However, MIROCALS, a ld-IL-2 phase II clinical trial using 2MIU IL-2 is currently in 
the recruiting phase. Its purpose is to evaluate the clinical efficiency and safety of 2MIU 
IL-2 as an add-on therapy to riluzole in 216 ALS patients, recruited at diagnosis 
(https://clinicaltrials.gov/ct2/show/NCT03039673). Together with clinical evaluations, 
additional research including deep immune-phenotyping, genomics, blood 
transcriptomics as well as CNS biomarker analysis will be conducted to investigate the 
effect of ld-IL-2 on this patients (http://www.mirocals.eu/en/).  
Dimethyl fumarate (DMF)
This drug is currently approved by both the FDA and the EMA for the treatment of 
psoriasis and relapsing-remitting forms of multiple sclerosis (MS) with the commercial 
name of Tecfidera. Evidence shows that DMF exerts its beneficial effects by a dual 
mechanism. It promotes the antioxidant response through the activation of the nuclear 1 
factor (erythroid-derived 2)-like 2 (NRF2) pathway and it has immune modulatory 
properties. In fact, it stimulates type II dendritic cells which secrete the anti-
inflammatory IL-10, reduces in the synthesis of pro-inflammatory cytokines and 
promotes a shift in the T lymphocyte population (68, 69, 70). In particular, MS patients 
treated with DMF showed a significantly decrease Th1 cells proportion, while an 
increase in Th2 and Treg cells is documented, although, a different study reported the 
effect of Tregs to be of short term (71, 72). Moreover, DMF seems to increase the 
sensibility of Teffs to Tregs and in turns this promotes their suppression (73, 74). 
Given this background, DMF or Tecfidera is currently being investigated in a phase II 
clinical trial called TEALS. The aim of the study is to evaluate safety and efficacy of 
this treatment on 90 sporadic ALS patients 
(https://www.australianclinicaltrials.gov.au/anzctr/trial/ACTRN12618000534280) (75). 
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ALS is a fatal neurodegenerative disease and currently, there is no effective disease 
modifying therapy for this condition. A range of mechanisms contribute to the disease 
onset and progression. Amongst these, neuroinflammation has a key role and its 
potential efficacy as a therapeutic target is now of growing interest. However, drugs 
which indiscriminately suppress the immune system do not appear to be effective (50, 
51, 52, 53). Therefore, immunomodulatory treatments, which can re-establish the 
normal immune phenotype, could represent a more appropriate target. In particular, 
several trials, with the aim of expanding Tregs, are currently ongoing and after their 
completion we will understand whether this type of treatment has an effect on disease 
progression and/or patient survival. However, from preliminary studies, regulatory T 
cells seem to represent a promising therapeutic opportunity to restore the physiological 
equilibrium among immune cell types. 
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FIGURE AND TABLE LEGENDS
Figure 1: Mechanisms of action of Tregs. Summary of the different mechanisms of 
Treg-mediated immune suppression. A: Inhibitory cytokine release, B: Cytolysis 
induction, C: Metabolic disruption, D: CTLA4-mediated mechanism, E: cAMP-mediated 
mechanism.
Figure 2: The early phase versus the later phase of disease: focusing on the role of 
Tregs. The early phase is characterized by a recruitment of regulatory T cells in the 
CNS from the periphery (a). This is a neuroprotective attempt made by the CNS to 
reduce neuro-inflammation. At this stage, Tregs secrete anti-inflammatory compounds 
which promote the activation of M2 microglia known for their anti-inflammatory 
properties. In the later stage, as the disease progresses, the number of Tregs in the 
CNS  decreases, while inflammatory mediators prevail (b). This includes Th1, which 
secretes cytokines that activate M1 microglia and promote inflammation and 
neurotoxicity. 
Table 1: Targeting Tregs: ongoing clinical trials
These ongoing clinical trials aim to expand the protective regulatory T cells. Names 
and IDs are reported together with drug information, phase of the study, status and 
number of participants involved. For more information, group divisions and treatment 
regimens are also described.  
Page 16 of 23
URL: http://mc.manuscriptcentral.com/als  Email: gerd.halvorsen@informa.com

































































1. Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. Amyotrophic lateral 
sclerosis. Nat Rev Dis Primers. 2017;3:17071.
2. Al-Chalabi A, Hardiman O, Kiernan MC, Chiò A, Rix-Brooks B, van den Berg LH. Amyotrophic lateral 
sclerosis: moving towards a new classification system. Lancet Neurol. 2016;15(11):1182-94.
3. Nagoshi N, Nakashima H, Fehlings MG. Riluzole as a neuroprotective drug for spinal cord injury: 
from bench to bedside. Molecules. 2015;20(5):7775-89.
4. Fang T, Al Khleifat A, Meurgey JH, Jones A, Leigh PN, Bensimon G, et al. Stage at which riluzole 
treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data 
from a dose-ranging study. Lancet Neurol. 2018.
5. Writing group on behalf of the Edavarone (MCI-186) ALS 19 study group. Open-label 24-week 
extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 
Frontotemporal Degener. 2017;18(sup1):55-63.
6. Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients 
with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 
2017;16(7):505-12.
7. Ferraiuolo L, Kirby J, Grierson AJ, Sendtner M, Shaw PJ. Molecular pathways of motor neuron injury 
in amyotrophic lateral sclerosis. Nat Rev Neurol. 2011;7(11):616-30.
8. Cozzolino M, Pesaresi MG, Gerbino V, Grosskreutz J, Carrì MT. Amyotrophic lateral sclerosis: new 
insights into underlying molecular mechanisms and opportunities for therapeutic intervention. Antioxid 
Redox Signal. 2012;17(9):1277-330.
9. Liu J, Wang F. Role of Neuroinflammation in Amyotrophic Lateral Sclerosis: Cellular Mechanisms 
and Therapeutic Implications. Front Immunol. 2017;8:1005.
10. Male M. BJ, Roth D. B., Roitt I. Immunology. Seventh Edition ed: Elsevier; 2006.
11. Mills KH. Regulatory T cells: friend or foe in immunity to infection? Nat Rev Immunol. 
2004;4(11):841-55.
12. Yadav M, Stephan S, Bluestone JA. Peripherally induced tregs - role in immune homeostasis and 
autoimmunity. Front Immunol. 2013;4:232.
13. Vent-Schmidt J, Han JM, MacDonald KG, Levings MK. The role of FOXP3 in regulating immune 
responses. Int Rev Immunol. 2014;33(2):110-28.
14. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T 
cells through GITR breaks immunological self-tolerance. Nat Immunol. 2002;3(2):135-42.
15. McHugh RS, Whitters MJ, Piccirillo CA, Young DA, Shevach EM, Collins M, et al. CD4(+)CD25(+) 
immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced 
TNF receptor. Immunity. 2002;16(2):311-23.
16. Ronchetti S, Ricci E, Petrillo MG, Cari L, Migliorati G, Nocentini G, et al. Glucocorticoid-induced 
tumour necrosis factor receptor-related protein: a key marker of functional regulatory T cells. J Immunol 
Res. 2015;2015:171520.
17. Wikenheiser DJ, Stumhofer JS. ICOS Co-Stimulation: Friend or Foe? Front Immunol. 2016;7:304.
18. Zheng J, Chan PL, Liu Y, Qin G, Xiang Z, Lam KT, et al. ICOS regulates the generation and function of 
human CD4+ Treg in a CTLA-4 dependent manner. PLoS One. 2013;8(12):e82203.
19. Landuyt AE, Klocke BJ, Colvin TB, Schoeb TR, Maynard CL. Cutting Edge: ICOS-Deficient Regulatory T 
Cells Display Normal Induction of. J Immunol. 2019;202(4):1039-44.
20. Garg G, Tyler JR, Yang JH, Cutler AJ, Downes K, Pekalski M, et al. Type 1 diabetes-associated IL2RA 
variation lowers IL-2 signaling and contributes to diminished CD4+CD25+ regulatory T cell function. J 
Immunol. 2012;188(9):4644-53.
21. Malek TR. The biology of interleukin-2. Annu Rev Immunol. 2008;26:453-79.
22. Malek TR, Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and 
immunity. Immunity. 2010;33(2):153-65.
Page 17 of 23
URL: http://mc.manuscriptcentral.com/als  Email: gerd.halvorsen@informa.com
































































23. Matsuoka K, Koreth J, Kim HT, Bascug G, McDonough S, Kawano Y, et al. Low-dose interleukin-2 
therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl 
Med. 2013;5(179):179ra43.
24. Zorn E, Nelson EA, Mohseni M, Porcheray F, Kim H, Litsa D, et al. IL-2 regulates FOXP3 expression in 
human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of 
these cells in vivo. Blood. 2006;108(5):1571-9.
25. Tang Q, Adams JY, Penaranda C, Melli K, Piaggio E, Sgouroudis E, et al. Central role of defective 
interleukin-2 production in the triggering of islet autoimmune destruction. Immunity. 2008;28(5):687-97.
26. Grinberg-Bleyer Y, Baeyens A, You S, Elhage R, Fourcade G, Gregoire S, et al. IL-2 reverses 
established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med. 
2010;207(9):1871-8.
27. Duffy SS, Keating BA, Perera CJ, Moalem-Taylor G. The role of regulatory T cells in nervous system 
pathologies. J Neurosci Res. 2018;96(6):951-68.
28. Liu G, Ma H, Qiu L, Li L, Cao Y, Ma J, et al. Phenotypic and functional switch of macrophages induced 
by regulatory CD4+CD25+ T cells in mice. Immunol Cell Biol. 2011;89(1):130-42.
29. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 
2008;8(7):523-32.
30. Gondek DC, Lu LF, Quezada SA, Sakaguchi S, Noelle RJ. Cutting edge: contact-mediated suppression 
by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J 
Immunol. 2005;174(4):1783-6.
31. Zhao DM, Thornton AM, DiPaolo RJ, Shevach EM. Activated CD4+CD25+ T cells selectively kill B 
lymphocytes. Blood. 2006;107(10):3925-32.
32. Cao X, Cai SF, Fehniger TA, Song J, Collins LI, Piwnica-Worms DR, et al. Granzyme B and perforin are 
important for regulatory T cell-mediated suppression of tumor clearance. Immunity. 2007;27(4):635-46.
33. de la Rosa M, Rutz S, Dorninger H, Scheffold A. Interleukin-2 is essential for CD4+CD25+ regulatory 
T cell function. Eur J Immunol. 2004;34(9):2480-8.
34. Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ. CD4+CD25+Foxp3+ regulatory T cells induce 
cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol. 2007;8(12):1353-62.
35. Fallarino F, Grohmann U, Hwang KW, Orabona C, Vacca C, Bianchi R, et al. Modulation of 
tryptophan catabolism by regulatory T cells. Nat Immunol. 2003;4(12):1206-12.
36. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat 
Rev Immunol. 2004;4(10):762-74.
37. Bopp T, Becker C, Klein M, Klein-Hessling S, Palmetshofer A, Serfling E, et al. Cyclic adenosine 
monophosphate is a key component of regulatory T cell-mediated suppression. J Exp Med. 
2007;204(6):1303-10.
38. Schmidt A, Oberle N, Krammer PH. Molecular mechanisms of treg-mediated T cell suppression. 
Front Immunol. 2012;3:51.
39. Mantovani S, Garbelli S, Pasini A, Alimonti D, Perotti C, Melazzini M, et al. Immune system 
alterations in sporadic amyotrophic lateral sclerosis patients suggest an ongoing neuroinflammatory 
process. J Neuroimmunol. 2009;210(1-2):73-9.
40. Beers DR, Henkel JS, Zhao W, Wang J, Huang A, Wen S, et al. Endogenous regulatory T lymphocytes 
ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with 
amyotrophic lateral sclerosis. Brain. 2011;134(Pt 5):1293-314.
41. Zhao W, Beers DR, Liao B, Henkel JS, Appel SH. Regulatory T lymphocytes from ALS mice suppress 
microglia and effector T lymphocytes through different cytokine-mediated mechanisms. Neurobiol Dis. 
2012;48(3):418-28.
42. Rentzos M, Evangelopoulos E, Sereti E, Zouvelou V, Marmara S, Alexakis T, et al. Alterations of T cell 
subsets in ALS: a systemic immune activation? Acta Neurol Scand. 2012;125(4):260-4.
43. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS 
functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group 
(Phase III). J Neurol Sci. 1999;169(1-2):13-21.
Page 18 of 23
URL: http://mc.manuscriptcentral.com/als  Email: gerd.halvorsen@informa.com
































































44. Beers DR, Zhao W, Wang J, Zhang X, Wen S, Neal D, et al. ALS patients' regulatory T lymphocytes 
are dysfunctional, and correlate with disease progression rate and severity. JCI Insight. 2017;2(5):e89530.
45. Appel V, Stewart SS, Smith G, Appel SH. A rating scale for amyotrophic lateral sclerosis: description 
and preliminary experience. Ann Neurol. 1987;22(3):328-33.
46. Henkel JS, Beers DR, Wen S, Rivera AL, Toennis KM, Appel JE, et al. Regulatory T-lymphocytes 
mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med. 2013;5(1):64-79.
47. Alsuliman A, Appel SH, Beers DR, Basar R, Shaim H, Kaur I, et al. A robust, good manufacturing 
practice-compliant, clinical-scale procedure to generate regulatory T cells from patients with amyotrophic 
lateral sclerosis for adoptive cell therapy. Cytotherapy. 2016;18(10):1312-24.
48. Delgoffe GM, Kole TP, Zheng Y, Zarek PE, Matthews KL, Xiao B, et al. The mTOR kinase differentially 
regulates effector and regulatory T cell lineage commitment. Immunity. 2009;30(6):832-44.
49. Sheean RK, McKay FC, Cretney E, Bye CR, Perera ND, Tomas D, et al. Association of Regulatory T-Cell 
Expansion With Progression of Amyotrophic Lateral Sclerosis: A Study of Humans and a Transgenic Mouse 
Model. JAMA Neurol. 2018.
50. Tan E, Lynn DJ, Amato AA, Kissel JT, Rammohan KW, Sahenk Z, et al. Immunosuppressive treatment 
of motor neuron syndromes. Attempts to distinguish a treatable disorder. Arch Neurol. 1994;51(2):194-
200.
51. Cudkowicz ME, Shefner JM, Schoenfeld DA, Zhang H, Andreasson KI, Rothstein JD, et al. Trial of 
celecoxib in amyotrophic lateral sclerosis. Ann Neurol. 2006;60(1):22-31.
52. Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, et al. Efficacy of minocycline 
in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 2007;6(12):1045-
53.
53. Stommel EW, Cohen JA, Fadul CE, Cogbill CH, Graber DJ, Kingman L, et al. Efficacy of thalidomide for 
the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial. Amyotroph Lateral Scler. 
2009;10(5-6):393-404.
54. Mandrioli J, D'Amico R, Zucchi E, Gessani A, Fini N, Fasano A, et al. Rapamycin treatment for 
amyotrophic lateral sclerosis: Protocol for a phase II randomized, double-blind, placebo-controlled, 
multicenter, clinical trial (RAP-ALS trial). Medicine (Baltimore). 2018;97(24):e11119.
55. Caccamo A, Majumder S, Deng JJ, Bai Y, Thornton FB, Oddo S. Rapamycin rescues TDP-43 
mislocalization and the associated low molecular mass neurofilament instability. J Biol Chem. 
2009;284(40):27416-24.
56. Staats KA, Hernandez S, Schönefeldt S, Bento-Abreu A, Dooley J, Van Damme P, et al. Rapamycin 
increases survival in ALS mice lacking mature lymphocytes. Mol Neurodegener. 2013;8:31.
57. Cheng CW, Lin MJ, Shen CK. Rapamycin alleviates pathogenesis of a new Drosophila model of ALS-
TDP. J Neurogenet. 2015;29(2-3):59-68.
58. Madill M, McDonagh K, Ma J, Vajda A, McLoughlin P, O'Brien T, et al. Amyotrophic lateral sclerosis 
patient iPSC-derived astrocytes impair autophagy via non-cell autonomous mechanisms. Mol Brain. 
2017;10(1):22.
59. Zhang X, Li L, Chen S, Yang D, Wang Y, Wang Z, et al. Rapamycin treatment augments motor neuron 
degeneration in SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Autophagy. 2011;7(4):412-25.
60. Thonhoff JR, Beers DR, Zhao W, Pleitez M, Simpson EP, Berry JD, et al. Expanded autologous 
regulatory T-lymphocyte infusions in ALS: A phase I, first-in-human study. Neurol Neuroimmunol 
Neuroinflamm. 2018;5(4):e465.
61. Vallarola A, Sironi F, Tortarolo M, Gatto N, De Gioia R, Pasetto L, et al. RNS60 exerts therapeutic 
effects in the SOD1 ALS mouse model through protective glia and peripheral nerve rescue. J 
Neuroinflammation. 2018;15(1):65.
62. Paganoni S, Alshikho MJ, Luppino S, Chan J, Pothier L, Schoenfeld D, et al. A pilot trial of RNS60 in 
amyotrophic lateral sclerosis. Muscle Nerve. 2019;59(3):303-8.
63. Goldsmith JR. Vitamin D as an Immunomodulator: Risks with Deficiencies and Benefits of 
Supplementation. Healthcare (Basel). 2015;3(2):219-32.
64. Karam C, Barrett MJ, Imperato T, MacGowan DJ, Scelsa S. Vitamin D deficiency and its 
supplementation in patients with amyotrophic lateral sclerosis. J Clin Neurosci. 2013;20(11):1550-3.
Page 19 of 23
URL: http://mc.manuscriptcentral.com/als  Email: gerd.halvorsen@informa.com
































































65. Camu W, Tremblier B, Plassot C, Alphandery S, Salsac C, Pageot N, et al. Vitamin D confers 
protection to motoneurons and is a prognostic factor of amyotrophic lateral sclerosis. Neurobiol Aging. 
2014;35(5):1198-205.
66. Blasco H, Madji Hounoum B, Dufour-Rainfray D, Patin F, Maillot F, Beltran S, et al. Vitamin D is Not a 
Protective Factor in ALS. CNS Neurosci Ther. 2015;21(8):651-6.
67. Dupont G, Demaret J, Venet F, Malergue F, Malcus C, Poitevin-Later F, et al. Comparative dose-
responses of recombinant human IL-2 and IL-7 on STAT5 phosphorylation in CD4+FOXP3- cells versus 
regulatory T cells: a whole blood perspective. Cytokine. 2014;69(1):146-9.
68. Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al. Placebo-controlled phase 3 
study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098-107.
69. Linker RA, Lee DH, Ryan S, van Dam AM, Conrad R, Bista P, et al. Fumaric acid esters exert 
neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain. 
2011;134(Pt 3):678-92.
70. Ghoreschi K, Brück J, Kellerer C, Deng C, Peng H, Rothfuss O, et al. Fumarates improve psoriasis and 
multiple sclerosis by inducing type II dendritic cells. J Exp Med. 2011;208(11):2291-303.
71. Gross CC, Schulte-Mecklenbeck A, Klinsing S, Posevitz-Fejfár A, Wiendl H, Klotz L. Dimethyl 
fumarate treatment alters circulating T helper cell subsets in multiple sclerosis. Neurol Neuroimmunol 
Neuroinflamm. 2016;3(1):e183.
72. Holm Hansen R, Højsgaard Chow H, Christensen JR, Sellebjerg F, von Essen MR. Dimethyl fumarate 
therapy reduces memory T cells and the CNS migration potential in patients with multiple sclerosis. Mult 
Scler Relat Disord. 2019;37:101451.
73. Schlöder J, Berges C, Luessi F, Jonuleit H. Dimethyl Fumarate Therapy Significantly Improves the 
Responsiveness of T Cells in Multiple Sclerosis Patients for Immunoregulation by Regulatory T Cells. Int J 
Mol Sci. 2017;18(2).
74. Kornberg MD, Bhargava P, Kim PM, Putluri V, Snowman AM, Putluri N, et al. Dimethyl fumarate 
targets GAPDH and aerobic glycolysis to modulate immunity. Science. 2018;360(6387):449-53.
75. Vucic S, Ryder J, Mekhael L, Rd H, Mathers S, Needham M, et al. Phase 2 randomized placebo 
controlled double blind study to assess the efficacy and safety of tecfidera in patients with amyotrophic 
lateral sclerosis (TEALS Study): Study protocol clinical trial (SPIRIT Compliant). Medicine (Baltimore). 
2020;99(6):e18904.
Page 20 of 23
URL: http://mc.manuscriptcentral.com/als  Email: gerd.halvorsen@informa.com

































































Figure 1: Mechanisms of action of Tregs. Summary of the different mechanisms of Treg-mediated immune 
suppression. A: Inhibitory cytokine release, B: Cytolysis induction, C: Metabolic disruption, D: CTLA4-
mediated mechanism, E: cAMP-mediated mechanism. 
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Figure 2: The early phase versus the later phase of disease: focusing on the role of Tregs. The early phase is 
characterized by a recruitment of regulatory T cells in the CNS from the periphery (a). This is a 
neuroprotective attempt made by the CNS to reduce neuro-inflammation. At this stage, Tregs secrete anti-
inflammatory compounds which promote the activation of M2 microglia known for their anti-inflammatory 
properties. In the later stage, as the disease progresses, the number of Tregs in the CNS  decreases, while 
inflammatory mediators prevail (b). This includes Th1, which secretes cytokines that activate M1 microglia 
and promote inflammation and neurotoxicity. 
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Trial name Drug Clinical trial ID Trial 
phase
Status Participants Group division and treatment types
RAP-ALS Rapamycin NCT03359538 Phase II Active, not 
recruiting
63 21 patients: placebo
21 patients: 1mg/m2/day rapamycin
21 patients: 2mg/m2/day rapamycin
1 administration daily for 18 weeks
T-regulatory in 




NCT04055623 Phase IIa Active, not 
recruiting
12 The study is divided in 2 parts:
1.  First 6 months: 
-Treated patients: Treg will be taken, expanded in lab and 
reinjected each month + ld-IL2 subcutaneous injections 3 
times per week
-Placebo patients: monthly placebo infusions + 3 placebo 
subcutaneous injection per week. 
2.  Second 6 months: all participants will receive autologous 
expanded Tregs monthly + ld-IL2 3 times weekly. 
The effect of 





NCT03456882 Phase II Active, not 
recruiting
142 71 patients: placebo
71 patients: RNS60 (normal saline plus oxygen in 
nanobubbles)
1 intravenous infusion per week and 1 nebulized inhalation 
daily for 24 weeks.
Nebulised RNS60 




NCT02988297 Phase II Not yet 
recruiting
140 70 patients: placebo
70 patients: RNS60
Daily inhalation for 24 weeks
VITALS Vitamin D 
(VD)
NCT02756104 NA Recruiting 97 27 healthy volunteers
70 ALS patients: VD-deficient patients will be supplemented 
for 6 months
MIROCALS ld-IL-2 NCT03039673 Phase II Active, not 
recruiting
216 108 patients: placebo
108 patients: 2MIU IL-2




ACTRN12618000534280 Phase II Not yet 
recruiting
90 30 patients: placebo
60 patients: 240mg of Tecfidera (oral tablets) 
Two administrations daily for 36 weeks. 
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